BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25564064)

  • 1. [Clinical observation of the salvage therapy using pegylated recombinant human granulocyte colony stimulating factor for grade IV neutropenia induced by concurrent chemoradiotherapy].
    Wu F; Wang H; Li N; Guo Y; Cheng Y; Liu Q; Yang X; Wan X; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):708-12. PubMed ID: 25564064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia.
    Wu FP; Wang J; Wang H; Li N; Guo Y; Cheng YJ; Liu Q; Yang XR
    Exp Ther Med; 2015 Mar; 9(3):761-765. PubMed ID: 25667625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
    Shi YK; Liu P; Yang S; Han XH; He XH; Ai B; Qin Y; Li B; Huang DZ; Zhang CG; Sun Y
    Ai Zheng; 2006 Apr; 25(4):495-500. PubMed ID: 16613688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
    Huang W; Liu J; Zeng Y; Wu F; Li N; Chen K; Hong Y; Wang L; Zhen H; Lin L
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer.
    Zou D; Guo M; Zhou Q
    BMC Cancer; 2021 Jun; 21(1):661. PubMed ID: 34078317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.
    Hu C; Ji B; Hu X; Yang C; Sun W; Zhao X; Li L; Li X; Zhang L
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):291-298. PubMed ID: 32567217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a prospective control trial].
    Yang WY; Liu TF; Chen XJ; Guo Y; Li T; Qi BQ; Liu F; Chang LX; Ruan M; Liu XM; Zhang L; Zou Y; Chen YM; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2020 Nov; 22(11):1172-1177. PubMed ID: 33172550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial.
    Wang C; Zhu S; Miao C; Wang Y; Chen J; Yuan S; Hu X
    BMC Cancer; 2022 May; 22(1):542. PubMed ID: 35562713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
    Xu B; Tian F; Yu J; Song Y; Shi J; Zhang B; Zhang Y; Yuan Z; Wu Q; Zhang Q; Nan K; Sun Q; Li W; Hu J; Bi J; Meng C; Dai H; Jiang H; Yue S; Cao B; Sun Y; Wang S; Tong Z; Shen P; Wu G; Tang L; Deng Y; Jia L; Shen K; Zhuang W; Xie X; Wu Y; Chen L
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):23-7. PubMed ID: 26796802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of PEG-rhG-CSF in preventing chemoradiotherapy-induced neutropenia in patients with locally advanced cervical cancer.
    Li W; Dong M; Huang S; Shi L; Yang H; Zhang Y; Gong J; Shi M; Wei L; Zhao L
    Biomol Biomed; 2023 Mar; 23(2):310-316. PubMed ID: 36300280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
    Ji X; Xu L; Pan P; Xu Z; Wang A; Li Y
    Thorac Cancer; 2022 Jan; 13(1):117-125. PubMed ID: 34791805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human granulocyte colony-stimulating factor may improve outcome attributable to neonatal sepsis complicated by neutropenia.
    Kocherlakota P; La Gamma EF
    Pediatrics; 1997 Jul; 100(1):E6. PubMed ID: 9200380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
    Jiang Y; Zhang J; Zhong J; Liao H; Zhang J; Liu Y; Liang Y; Li H
    BMC Cancer; 2023 Jul; 23(1):702. PubMed ID: 37495949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Prophylactic Administration of Granulocyte Colony-Stimulating Factor on Peripheral Leukocyte and Neutrophil Counts Levels After Chemotherapy in Patients With Early-Stage Breast Cancer: A Retrospective Cohort Study.
    Tian W; Wang Y; Zhou Y; Yao Y; Deng Y
    Front Oncol; 2022; 12():777602. PubMed ID: 35547875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental study on safety for granulopoiesis in simultaneous therapy with recombinant human granulocyte colony-stimulating factor and chemotherapy.
    Kabaya K; Obuchi M; Watanabe M; Kusaka M; Seki M
    Oncol Res; 1995; 7(3-4):165-71. PubMed ID: 8555650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF).
    Huang X; Li S; Shi W; Wang Y; Wan X; He J; Xu Y; Zhang W; Shi X; Chen R; Xu L; Zha X; Wang J
    Br J Clin Pharmacol; 2023 Jan; 89(1):372-379. PubMed ID: 36001055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A multicenter, randomized, controlled, phase Ⅳ clinical study of PEG-rhG-CSF for preventing chemotherapy induced neutropenia in patients with breast cancer].
    Jiang ZF; Xu FR; Fan J; Li BJ; Gao JN; Hu JW; Wang XJ; Zhang YQ; Wang JH; Li F; Liu Q; Liu YH; Wang S; Wang YS; Ouyang QC; Hu B; Sun GP; Zhang Y; Zang AM; Fan PZ; Wu CP; Liu J; Zhang HW; Wang W; Hu XC; Tang LL; Zhang J; Bao YY; Geng CZ; Sun Q; Zhang F; Yin YM; Jiang HC; An YH
    Zhonghua Yi Xue Za Zhi; 2018 Apr; 98(16):1231-1235. PubMed ID: 29747310
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics and safety of pegylated recombinant human granulocyte colony-stimulating factor in children with acute leukaemia.
    Liu XT; Zhao YX; Jia GW; Yang F; Zhang CZ; Han B; Dai JH; Han YQ; Tang BH; Yang XM; Shi HY; Zhou Y; Sui ZG; Chen JZ; van den Anker JN; Zhao W
    Br J Clin Pharmacol; 2021 Aug; 87(8):3292-3300. PubMed ID: 33506975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.